Apellis Pharmaceuticals Inc
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 16 | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | +38,599.7% | -100.0% | – | +806.9% | +967.1% | -76.1% | +13.5% | +35.1% | +2.8% | +97.9% | +111.8% | +16.2% | +32.6% | +17.7% | +15.9% | -1.4% | +8.0% | -21.5% | +7.0% | +156.9% | -56.4% | +34.2% | – | |
| – | – | – | – | – | – | -100.0% | – | +56.2% | +6.9% | -100.0% | – | +30.5% | +10.2% | -99.7% | -34.2% | -14.1% | +76,299.2% | -99.7% | +40.7% | +36,941.4% | -99.9% | +182.6% | +196.2% | -93.4% | +1,584.1% | +111.8% | +167.0% | +7.3% | +167.5% | -11.1% | +3.7% | +14.0% | +42.5% | +21.8% | -15.9% | -59.0% | +74.3% | +21.1% | +37.4% | – | |
| – | – | – | – | – | – | – | -185,839.0% | – | – | – | -421,612.7% | – | – | – | – | – | – | +38,556.3% | -100.2% | – | – | +988.3% | -78.1% | +23.6% | +27.3% | -4.5% | +87.6% | +133.8% | +1.6% | +43.7% | +19.9% | +16.1% | -7.3% | +5.1% | -22.9% | +24.2% | +164.0% | -60.8% | +33.6% | – | |
| – | +11.8% | -10.3% | +29.3% | +44.1% | -8.7% | +38.0% | +32.5% | +58.2% | +7.3% | +4.3% | +31.4% | +25.2% | +1.2% | +52.9% | -11.7% | +25.7% | +7.0% | -19.1% | +11.4% | +73.7% | -39.9% | +23.3% | -15.9% | +11.8% | -6.3% | +4.4% | +10.7% | -13.1% | -17.0% | -12.8% | +22.3% | -8.0% | +13.6% | -13.8% | +13.2% | -22.5% | +1.7% | +8.9% | +3.7% | – | |
| – | -9.7% | +8.7% | +67.5% | -6.1% | +21.1% | +134.7% | -17.0% | +47.4% | +5.3% | +2.0% | +27.9% | +56.4% | +45.8% | +47.5% | +7.4% | -3.7% | +30.2% | +20.3% | -8.8% | +20.7% | -6.5% | -9.4% | +23.5% | +23.5% | +24.1% | +7.6% | +21.0% | +9.1% | +30.8% | -2.7% | -8.6% | -1.1% | -4.8% | -68.7% | +238.8% | +1.4% | +8.8% | +3.1% | -15.5% | – | |
| – | +8.8% | -7.7% | +35.5% | +34.0% | -4.5% | +55.3% | +19.1% | +56.2% | +6.9% | +3.9% | +30.8% | +30.5% | +10.2% | +51.1% | -6.7% | +17.0% | +12.8% | -8.1% | +3.8% | -60.6% | +172.6% | +11.8% | -4.8% | +16.0% | +5.3% | +5.9% | +15.4% | -2.4% | +8.7% | -6.3% | +1.3% | -3.8% | +2.4% | -6.0% | +9.1% | -8.4% | +6.7% | +5.0% | -9.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -195.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -122.9% | – | – | |
| – | – | – | -74.1% | +200.0% | +0.0% | -66.7% | +175.2% | -31.0% | +52.7% | +122.3% | -4.9% | -73.1% | +277.0% | +553.5% | -0.3% | +76.3% | +37.5% | +1.2% | -56.6% | -9.8% | -39.4% | +32.3% | +182.9% | -1.1% | -6.5% | -2.1% | -2.7% | -2.5% | -0.4% | +1.3% | -5.9% | +34.3% | +33.9% | -8.0% | -4.2% | +0.9% | +1.1% | -3.8% | -4.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -329.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -127.1% | – | – | |
| – | -19,302.1% | – | – | – | – | – | – | -12,725.0% | – | – | -85.7% | +13.9% | +39.3% | +636.8% | -1.2% | +75.8% | +37.2% | -80.5% | +210.0% | -35.2% | -41.6% | -90.9% | +516.3% | -59.8% | -8.2% | -429.8% | – | -31.2% | +20.1% | +510.7% | -88.1% | -32.9% | +419.3% | -51.7% | +19.2% | +36.7% | +29.2% | -48.0% | +58.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -334.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -127.3% | – | – | |
| – | -19,302.1% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -299.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -120.8% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.